Pear Therapeutics (PEAR) reported Q3 EPS of ($0.22), $0.01 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $4.1 million versus the consensus estimate of $4.34 million.
Pear Therapeutics (PEAR) reported Q3 EPS of ($0.22), $0.01 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $4.1 million versus the consensus estimate of $4.34 million.